Mei-Jung Lai - 臺北醫學大學

查看斯高帕斯 (Scopus) 概要

No. 250 Wu-Xing Street, Taipei 11031

h-index

每年研究成果

學歷

2010 臺北醫學大學藥學系博士
2006 University of Sourhern CaliforniaPharmaceutical Sciences 碩士
2001 臺北醫學大學藥學系學士

經歷

2019.12- 臺北醫學大學生技醫療產業研發博士學程副研究員
2019.02- 臺北醫學大學生技醫藥商品化中心副研究員
2018.04-2019.01 臺北醫學大學生技醫藥商品化中心助理研究員
2016.11-2018.03 臺北醫學大學癌症轉譯研究中心助理研究員
2014.08-2016.10 臺北醫學大學轉譯醫學研究中心助理研究員
2013.01-2014.07 臺北醫學大學博士後研究員
2012.03-2012.10 食品藥物管理局審查員
2010.08-2012.02 臺北醫學大學博士後研究員

研究興趣

有機合成

指紋

查看啟用 Mei-Jung Lai 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。

1 類似的個人檔案

5 已完成

合成可雙重抑制組織蛋白去乙醯酶6與熱休克蛋白90，並同時調節PD-L1之雜環類抗癌化合物
Lai, M.-J. (PI)
8/1/20 → 7/1/21
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
組蛋白去乙醯酶在血管認知功能損傷中的作用-組蛋白去乙醯酶調節者在血管認知損傷動物可作為新的治療
Lai, M.-J. (PI)
1/1/19 → 12/1/19
研究計畫: A - 政府部門 › d - 教育部
設計與合成聯芳基及二苯胺基取代之磺胺類抗癌化合物
Lai, M.-J. (PI)
8/1/16 → 7/31/17
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
TMU103-AE1-B09
Lai, M.-J. (PI)
11/1/14 → 10/31/16
研究計畫: B - 校內計畫 › g - 新聘教師研究補助
設計與合成新穎苯甲醯胺與醯基羥胺取代之雜環化合物分別抑制微小管與組織蛋白去乙醯酉每6為抗癌藥物
Lai, M.-J. (PI)
11/1/14 → 10/31/15
研究計畫: A - 政府部門 › b - 國家科學及技術委員會

51 文章
4 評論/辯論

Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents
Sethy, B., Yu, Z. Y., Narwanti, I., Upadhyay, R., Lai, M. J., Lee, S. B. & Liou, J. P., 12月 2024, 於: Bioorganic Chemistry. 153, 107771.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress
Sharma, R., Chiang, Y. H., Chen, H. C., Lin, H. Y., Yang, W. B., Nepali, K., Lai, M. J., Chen, K. Y., Liou, J. P. & Hsu, T. I., 4月 1 2024, 於: Cancer Letters. 586, 216666.
研究成果: 雜誌貢獻 › 文章 › 同行評審
3 引文斯高帕斯（Scopus）
First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo
Sharma, S., Wang, S. A., Yang, W. B., Lin, H. Y., Lai, M. J., Chen, H. C., Kao, T. Y., Hsu, F. L., Nepali, K., Hsu, T. I. & Liou, J. P., 2月 22 2024, 於: Journal of Medicinal Chemistry. 67, 4, p. 2963-2985 23 p.
研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取
3 引文斯高帕斯（Scopus）
HSP90/LSD1 dual inhibitors against prostate cancer as well as patient-derived colorectal organoids
Tang, D. W., Chen, I. C., Chou, P. Y., Lai, M. J., Liu, Z. Y., Tsai, K. K., Cheng, L. H., Zhao, J. X., Cho, E. C., Chang, H. H., Lin, T. E., Hsu, K. C., Chen, M. C. & Liou, J. P., 11月 15 2024, 於: European Journal of Medicinal Chemistry. 278, 116801.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids
Chou, P. Y., Lai, M. J., Tsai, K. K., Cheng, L. H., Wu, Y. W., Chen, M. C., Pan, S. L., Ho, H. O., Nepali, K. & Liou, J. P., 2024, (接受/付印) 於: Journal of Medicinal Chemistry. 67, 19, p. 17207-17225 19 p.
研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.c.4522856.v1, https://springernature.figshare.com/collections/Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/4522856/1
資料集: Dataset
Additional file 5: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chang, L.-H. (Contributor), Liou, J.-P. (Creator), Lai, M.-J. (Contributor), Chang, C.-D. (Contributor), Tu, H.-J. (Contributor), Chao, M.-W. (Contributor), Pan, S.-L. (Contributor), Chen, Y.-Y. (Creator) & Teng, C.-M. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202902.v1, https://doi.org/10.6084%2Fm9.figshare.8202902.v1
資料集: Dataset
Additional file 2: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202887.v1, https://springernature.figshare.com/articles/Additional_file_2_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202887/1
資料集: Dataset
Additional file 1: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202881.v1, https://springernature.figshare.com/articles/Additional_file_1_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202881/1
資料集: Dataset
Additional file 4: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202896.v1, https://springernature.figshare.com/articles/Additional_file_4_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202896/1
資料集: Dataset